Medicine

AbbVie, Gedeon Richter Ink Deal to Develop Novel Targets for Neuropsychiatric Conditions

Under terms of the deal, Richter will receive an upfront cash payment of $25 million, along with potential future development, regulatory, and commercialization milestones.

Leave a Reply

Your email address will not be published. Required fields are marked *